Skip to main content

Table 1 Summary table of main experimental parameters and outcome as determined by the meta-analysis of cancer cytotherapy studies using naïve (unmodified) MSC

From: Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review

Consolidated groups N MSC MSC N Tumors most frequently targeted (%) Tumor target frequency (%) Mean antitumor effect*
In vivo (naïve) 30 AT 5 Brain/neural 60 ND
BM 20 Breast 25 ND
  Colorectal 25 ND
UC 5 Breast 40 ND
In vitro (naïve) 53 AT 10 Breast 30 ND
BM 22 Breast 32 ??
UC 21 Breast 33 ANTI-
In vitro + in vivo (naïve) 83 AT 15 Brain/Neural 40 ??
BM 42 Breast 29 PRO+
  Colorectal 19 PRO+
UC 26 Breast 31 ANTI-
In vitro + in vivo x(naïve+naïve as CTRL for GM) 126 AT 31 Brain/Neural 32 ANTI-/NEUTRAL
BM 59 Breast 24 PRO+
  Colorectal 15 PRO+
  Liver 12 ??
UC 36 Breast 33 ANTI-
  Lung 17 ANTI-
  1. Findings based both on studies focusing solely on naïve MSC, as well as on selected studies where these cells were used as controls for experiments focusing on genetically modified MSC (GM-MSC) are shown. Results are listed in consolidated groups of increasing size (number of observations = N). MSC N column depicts MSC sample size. Primary outcomes include percentage of the most frequently targeted tumor types by the respective MSC, as well the mean anti-cancer effect for each MSC (effector): tumor combination. The minimum accepted number of MSC (cut-off) most commonly associated with respective tumors was set to six
  2. *PRO+ denotes tumor-promoting effect exerted by >50% of the associated MSC
  3. ANTI denotes inhibition of tumor by >50% of the associated MSC
  4. ?? denotes no clear effect
  5. ND not determined due to insufficient data (N < cut-off)